Fibromyalgia
Low-dose naltrexone for the treatment of fibromyalgia: Findings of a small, randomized, double-blind, placebo-controlled, counterbalanced, crossover trial assessing daily pain levels†
Jarred Younger,
Noorulain Noor,
Rebecca McCue,
Sean Mackey,
Corresponding Author
Jarred Younger
Stanford University School of Medicine, Palo Alto, California
Department of Anesthesia, Stanford University School of Medicine, 780 Welch Road, Suite 207F, Palo Alto, CA 94304-1573Search for more papers by this authorNoorulain Noor
Stanford University School of Medicine, Palo Alto, California
Search for more papers by this authorRebecca McCue
Stanford University School of Medicine, Palo Alto, California
Search for more papers by this authorSean Mackey
Stanford University School of Medicine, Palo Alto, California
Search for more papers by this authorJarred Younger,
Noorulain Noor,
Rebecca McCue,
Sean Mackey,
Corresponding Author
Jarred Younger
Stanford University School of Medicine, Palo Alto, California
Department of Anesthesia, Stanford University School of Medicine, 780 Welch Road, Suite 207F, Palo Alto, CA 94304-1573Search for more papers by this authorNoorulain Noor
Stanford University School of Medicine, Palo Alto, California
Search for more papers by this authorRebecca McCue
Stanford University School of Medicine, Palo Alto, California
Search for more papers by this authorSean Mackey
Stanford University School of Medicine, Palo Alto, California
Search for more papers by this author†
ClinicalTrials.gov identifier: NCT00568555.
Abstract
Objective
To determine whether low dosages (4.5 mg/day) of naltrexone reduce fibromyalgia severity as compared with the nonspecific effects of placebo. In this replication and extension study of a previous clinical trial, we tested the impact of low-dose naltrexone on daily self-reported pain. Secondary outcomes included general satisfaction with life, positive mood, sleep quality, and fatigue.
Methods
Thirty-one women with fibromyalgia participated in the randomized, double-blind, placebo-controlled, counterbalanced, crossover study. During the active drug phase, participants received 4.5 mg of oral naltrexone daily. An intensive longitudinal design was used to measure daily levels of pain.
Results
When contrasting the condition end points, we observed a significantly greater reduction of baseline pain in those taking low-dose naltrexone than in those taking placebo (28.8% reduction versus 18.0% reduction; P = 0.016). Low-dose naltrexone was also associated with improved general satisfaction with life (P = 0.045) and with improved mood (P = 0.039), but not improved fatigue or sleep. Thirty-two percent of participants met the criteria for response (defined as a significant reduction in pain plus a significant reduction in either fatigue or sleep problems) during low-dose naltrexone therapy, as contrasted with an 11% response rate during placebo therapy (P = 0.05). Low-dose naltrexone was rated equally tolerable as placebo, and no serious side effects were reported.
Conclusion
The preliminary evidence continues to show that low-dose naltrexone has a specific and clinically beneficial impact on fibromyalgia pain. The medication is widely available, inexpensive, safe, and well-tolerated. Parallel-group randomized controlled trials are needed to fully determine the efficacy of the medication.
REFERENCES
- 1 Younger J, Mackey S. Fibromyalgia symptoms are reduced by low-dose naltrexone: a pilot study. Pain Med 2009; 10: 663–72.
- 2 Smith JP, Stock H, Bingaman S, Mauger D, Rogosnitzky M, Zagon IS. Low-dose naltrexone therapy improves active Crohn's disease. Am J Gastroenterol 2007; 102: 820–8.
- 3 Smith JP, Bingaman SI, Ruggiero F, Mauger DT, Mukherjee A, McGovern CO, et al. Therapy with the opioid antagonist naltrexone promotes mucosal healing in active Crohn's disease: a randomized placebo-controlled trial. Dig Dis Sci 2011; 56: 2088–97.
- 4 Cree BA, Kornyeyeva E, Goodin DS. Pilot trial of low-dose naltrexone and quality of life in multiple sclerosis. Ann Neurol 2010; 68: 145–50.
- 5 Sharafaddinzadeh N, Moghtaderi A, Kashipazha D, Majdinasab N, Shalbafan B. The effect of low-dose naltrexone on quality of life of patients with multiple sclerosis: a randomized placebo-controlled trial. Mult Scler 2010; 16: 964–9.
- 6 Frech T, Novak K, Revelo MP, Murtaugh M, Markewitz B, Hatton N, et al. Low-dose naltrexone for pruritus in systemic sclerosis. Int J Rheumatol 2011; 2011: 804296.
- 7 Brown N, Panksepp J. Low-dose naltrexone for disease prevention and quality of life. Med Hypotheses 2009; 72: 333–7.
- 8 Hutchinson MR, Zhang Y, Brown K, Coats BD, Shridhar M, Sholar PW, et al. Non-stereoselective reversal of neuropathic pain by naloxone and naltrexone: involvement of Toll-like receptor 4 (TLR4). Eur J Neurosci 2008; 28: 20–9.
- 9 Liu B, Du L, Hong JS. Naloxone protects rat dopaminergic neurons against inflammatory damage through inhibition of microglia activation and superoxide generation. J Pharmacol Exp Ther 2000; 293: 607–17.
- 10 Mattioli TA, Milne B, Cahill CM. Ultra-low dose naltrexone attenuates chronic morphine-induced gliosis in rats. Mol Pain 2010; 6: 22.
- 11 Lynch MA. The multifaceted profile of activated microglia. Mol Neurobiol 2009; 40: 139–56.
- 12 Watkins LR, Hutchinson MR, Ledeboer A, Wieseler-Frank J, Milligan ED, Maier SF. Glia as the “bad guys”: implications for improving clinical pain control and the clinical utility of opioids. Brain Behav Immun 2007; 21: 131–46.
- 13 Kettenmann H, Hanisch UK, Noda M, Verkhratsky A. Physiology of microglia. Physiol Rev 2011: 91: 461–553.
- 14 Myers JS. Proinflammatory cytokines and sickness behavior: implications for depression and cancer-related symptoms. Oncol Nurs Forum 2008; 35: 802–7.
- 15 Wolfe F, Ross K, Anderson J, Russell IJ, Hebert L. The prevalence and characteristics of fibromyalgia in the general population. Arthritis Rheum 1995; 38: 19–28.
- 16 Wolfe F, Smythe HA, Yunus MB, Bennett RM, Bombardier C, Goldenberg DL, et al. The American College of Rheumatology 1990 criteria for the classification of fibromyalgia: report of the Multicenter Criteria Committee. Arthritis Rheum 1990; 33: 160–72.
- 17 Wolfe F, Clauw DJ, FitzCharles MA, Goldenberg DL, Katz RS, Mease P, et al. The American College of Rheumatology preliminary diagnostic criteria for fibromyalgia and measurement of symptom severity. Arthritis Care Res (Hoboken) 2010; 62: 600–10.
- 18 Staud R. Evidence for shared pain mechanisms in osteoarthritis, low back pain, and fibromyalgia. Curr Rheumatol Rep 2011; 13: 513–20.
- 19 Woolf CJ. Central sensitization: implications for the diagnosis and treatment of pain. Pain 2011; 152: S2–15.
- 20 Burckhardt CS, Clark SR, Bennett RM. The fibromyalgia impact questionnaire: development and validation. J Rheumatol 1991; 18: 728–33.
- 21 Beck AT, Steer RA, Ball R, Ranieri W. Comparison of Beck Depression Inventories -IA and -II in psychiatric outpatients. J Pers Assess 1996; 67: 588–97.
- 22 Turk DC, Dworkin RH, Burke LB, Gershon R, Rothman M, Scott J, et al. Developing patient-reported outcome measures for pain clinical trials: IMMPACT recommendations. Pain 2006; 125: 208–15.
- 23 Arnold LM, Williams DA, Hudson JI, Martin SA, Clauw DJ, Crofford LJ, et al. Development of responder definitions for fibromyalgia clinical trials. Arthritis Rheum 2012; 64: 885–94.
- 24 Hains LE, Loram LC, Weiseler JL, Frank MG, Bloss EB, Sholar P, et al. Pain intensity and duration can be enhanced by prior challenge: initial evidence suggestive of a role of microglial priming. J Pain 2010; 11: 1004–14.
- 25 Dilger RN, Johnson RW. Aging, microglial cell priming, and the discordant central inflammatory response to signals from the peripheral immune system. J Leukoc Biol 2008; 84: 932–9.
- 26 Levesque S, Taetzsch T, Lull ME, Kodavanti U, Stadler K, Wagner A, et al. Diesel exhaust activates and primes microglia: air pollution, neuroinflammation, and regulation of dopaminergic neurotoxicity. Environ Health Perspect 2011; 119: 1149–55.
- 27 Carvey PM, Punati A, Newman MB. Progressive dopamine neuron loss in Parkinson's disease: the multiple hit hypothesis. Cell Transplant 2006; 15: 239–50.
- 28 Piche T, Gelsi E, Schneider SM, Hebuterne X, Giudicelli J, Ferrua B, et al. Fatigue is associated with high circulating leptin levels in chronic hepatitis C. Gut 2002; 51; 434–9.
- 29 Fukuda J, Nasu K, Sun B, Shang S, Kawano Y, Miyakawa I. Effects of leptin on the production of cytokines by cultured human endometrial stromal and epithelial cells. Fertil Steril 2003; 80 Suppl 2: 783–7.
- 30 White FA, Wilson NM. Chemokines as pain mediators and modulators. Curr Opin Anaesthesiol 2008; 21: 580–5.
- 31 White FA, Jung H, Miller RJ. Chemokines and the pathophysiology of neuropathic pain. Proc Natl Acad Sci U S A 2007; 104: 20151–8.
- 32 Wang H, Moser M, Schiltenwolf M, Buchner M. Circulating cytokine levels compared to pain in patients with fibromyalgia—a prospective longitudinal study over 6 months. J Rheumatol 2008; 35: 1366–70.
- 33 Abbadie C, Bhangoo S, De Koninck Y, Malcangio M, Melik-Parsadaniantz S, White FA. Chemokines and pain mechanisms. Brain Res Rev 2009; 60: 125–34.
- 34 Wieseler-Frank J, Maier SF, Watkins LR. Immune-to-brain communication dynamically modulates pain: physiological and pathological consequences. Brain Behav Immun 2005; 19: 104–11.
- 35 Zagon IS, Rahn KA, Turel AP, McLaughlin PJ. Endogenous opioids regulate expression of experimental autoimmune encephalomyelitis: a new paradigm for the treatment of multiple sclerosis. Exp Biol Med (Maywood) 2009; 234: 1383–92.
- 36 Narita M, Mizoguchi H, Nagase H, Suzuki T, Tseng LF. Up-regulation of spinal μ-opioid receptor function to activate G-protein by chronic naloxone treatment. Brain Res 2001; 913: 170–3.
- 37 Rajashekara V, Patel CN, Patel K, Purohit V, Yoburn BC. Chronic opioid antagonist treatment dose-dependently regulates μ-opioid receptors and trafficking proteins in vivo. Pharmacol Biochem Behav 2003; 75: 909–13.
- 38 Harris RE, Clauw DJ, Scott DJ, McLean SA, Gracely RH, Zubieta JK. Decreased central μ-opioid receptor availability in fibromyalgia. J Neurosci 2007; 27: 10000–6.
- 39 Yunus MB. Fibromyalgia and overlapping disorders: the unifying concept of central sensitivity syndromes. Semin Arthritis Rheum 2007; 36: 339–56.
- 40 Yunus MB. The prevalence of fibromyalgia in other chronic pain conditions. Pain Res Treat 2012; 2012: 584573.
- 41 Thiel A, Radlinska BA, Paquette C, Sidel M, Soucy JP, Schirrmacher R, et al. The temporal dynamics of poststroke neuroinflammation: a longitudinal diffusion tensor imaging-guided PET study with 11C-PK11195 in acute subcortical stroke. J Nucl Med 2010; 51: 1404–12.
- 42 Politis M, Pavese N, Tai YF, Kiferle L, Mason SL, Brooks DJ, et al. Microglial activation in regions related to cognitive function predicts disease onset in Huntington's disease: a multimodal imaging study. Hum Brain Mapp 2011; 32: 258–70.
- 43 Gulyas B, Vas A, Toth M, Takano A, Varrone A, Cselenyi Z, et al. Age and disease related changes in the translocator protein (TSPO) system in the human brain: positron emission tomography measurements with [11C]vinpocetine. NeuroImage 2011; 56: 1111–21.
- 44 Liu SL, Li YH, Shi GY, Chen YH, Huang CW, Hong JS, et al. A novel inhibitory effect of naloxone on macrophage activation and atherosclerosis formation in mice. J Am Coll Cardiol 2006; 48: 1871–9.
- 45 Thomas DM, Kuhn DM. MK-801 and dextromethorphan block microglial activation and protect against methamphetamine-induced neurotoxicity. Brain Res 2005; 1050: 190–8.
- 46 Zhang W, Qin L, Wang T, Wei SJ, Gao HM, Liu J, et al. 3-hydroxymorphinan is neurotrophic to dopaminergic neurons and is also neuroprotective against LPS-induced neurotoxicity. FASEB J 2005; 19: 395–7.
- 47 Mizuno T, Kurotani T, Komatsu Y, Kawanokuchi J, Kato H, Mitsuma N, et al. Neuroprotective role of phosphodiesterase inhibitor ibudilast on neuronal cell death induced by activated microglia. Neuropharmacology 2004; 46: 404–11.
- 48 Chechneva OV, Mayrhofer F, Daugherty DJ, Pleasure DE, Hong JS, Deng W. Low dose dextromethorphan attenuates moderate experimental autoimmune encephalomyelitis by inhibiting NOX2 and reducing peripheral immune cells infiltration in the spinal cord. Neurobiol Dis 2011; 44: 63–72.
- 49 Ponomarev ED, Veremeyko T, Barteneva N, Krichevsky AM, Weiner HL. MicroRNA-124 promotes microglia quiescence and suppresses EAE by deactivating macrophages via the C/EBP-α-PU.1 pathway. Nat Med 2011; 17: 64–70.
- 50 Amanzio M, Corazzini LL, Vase L, Benedetti F. A systematic review of adverse events in placebo groups of anti-migraine clinical trials. Pain 2009; 146: 261–9.
- 51 Pauer L, Winkelmann A, Arsenault P, Jespersen A, Whelan L, Atkinson G, et al, on behalf of the A0081100 Investigators. An international, randomized, double-blind, placebo-controlled, phase III trial of pregabalin monotherapy in treatment of patients with fibromyalgia. J Rheumatol 2011; 38: 2643–52.
- 52 Mease PJ, Russell IJ, Kajdasz DK, Wiltse CG, Detke MJ, Wohlreich MM, et al. Long-term safety, tolerability, and efficacy of duloxetine in the treatment of fibromyalgia. Semin Arthritis Rheum 2010; 39: 454–64.
- 53 Branco JC, Cherin P, Montagne A, Bouroubi A, on behalf of the Multinational Coordinator Study Group. Longterm therapeutic response to milnacipran treatment for fibromyalgia: a European 1-year extension study following a 3-month study. J Rheumatol 2011; 38: 1403–12.
- 54 Hauser W, Petzke F, Sommer C. Comparative efficacy and harms of duloxetine, milnacipran, and pregabalin in fibromyalgia syndrome. J Pain 2010; 11: 505–21.
- 55 Choy E, Marshall D, Gabriel ZL, Mitchell SA, Gylee E, Dakin HA. A systematic review and mixed treatment comparison of the efficacy of pharmacological treatments for fibromyalgia. Semin Arthritis Rheum 2011; 41: 335–45.e6.
